Peripheral Artery Disease Clinical Trial
— PESTO-AFCOfficial title:
Percutaneous Intervention Versus Surgery in the Treatment of Common Femoral Artery Lesions A Prospective, Multi-centre, Randomised Study
The endovascular therapy prevailed in nearly all regions of peripheral artery disease over
open surgery techniques. However, in treatment of the common femoral artery vascular surgery
is still the gold standard of therapy. One-year patency rates are between 90% and 95%. Today,
only in selected cases an endovascular procedure for common femoral artery diseases is
recommended.
The primary objective of this study is to compare the performance of directional atherectomy
and drug-coated balloon angioplasty over vascular surgery in common femoral artery lesions in
a prospective, multi-center, randomized clinical trial.
Status | Recruiting |
Enrollment | 306 |
Est. completion date | December 2021 |
Est. primary completion date | December 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 85 Years |
Eligibility |
Inclusion Criteria: 1. Subject must be between 21 and 85 years old; 2. Female of childbearing potential must have a negative pregnancy test within 10 days prior to index procedure and utilize reliable birth control until completion of the 12-month angiographic evaluation; 3. Clinical diagnosis of symptomatic peripheral artery disease defined by Rutherford 2, 3, or 4; 4. Common femoral artery (CFA) stenosis (including CFA bifurcation) >70% (visual estimate) or occlusion; Additional non-target lesion(s) in remaining non-target vessel(s), except ipsilateral iliac arteries, can be treated at the physician´s discretion; 5. At least one vessel outflow (infrapopliteal arteries) to the foot (without stenosis >50%). 6. Endovascular Procedure: successful target lesion crossing of the guidewire (guidewire located intraluminally); 7. Non-target lesion interventions (TASC A and B) to restore adequate blood flow, in the same index procedure are allowed. This intervention must be prior to the treatment of the study lesion and successful; 8. Willing to comply with the specified follow-up evaluation; 9. Written informed consent prior to any study procedures. Exclusion Criteria: 1. Ipsilateral significant (>50%) stenosis of the iliac arteries. 2. Significant (>50%) stenosis of all infrapopliteal arteries, no patent artery to the foot. 3. Angiographic evidence of thrombus within target vessel; 4. Thrombolysis within 72 hours prior to the index procedure; 5. In-Stent restenosis or restenosis of the native common femoral artery. 6. Aneurysm in the abdominal aorta or iliac arteries; 7. Concomitant hepatic insufficiency, thrombophlebitis, deep venous thrombus, coagulation disorder or receiving immunosuppressant therapy; 8. Recent MI or stroke < 30 days prior to the index procedure; 9. Life expectancy less than 24 months; 10. Known or suspected active infection at the time of the index procedure; 11. Known or suspected allergies or contraindications to aspirin, clopidogrel bisulfate (Plavix) and ticlopidine (Ticlid), heparin, or contrast agent; 12. Any significant medical condition which, in the investigator´s opinion, may interfere with the subject´s optimal participation in the study; 13. The subject is currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study. |
Country | Name | City | State |
---|---|---|---|
Germany | Universitäts-Herzzentrum Freiburg - Bad Krozingen | Bad Krozingen |
Lead Sponsor | Collaborator |
---|---|
Herz-Zentrums Bad Krozingen | Medtronic |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Rutherford-Becker class | Change in Rutherford-Becker class | 6, 12, and 24 months | |
Primary | Primary patency | Primary patency of the common femoral artery defined as freedom from target lesion restenosis (luminal narrowing of =50%) detected with duplex-ultrasound. The definition of a 50% restenosis is based on the peak systolic velocity ratio >2.4. | 12 month | |
Secondary | Primary patency | Primary patency of the common femoral artery defined as freedom from target lesion restenosis (luminal narrowing of =50%) detected with duplex-ultrasound. The definition of a 50% restenosis is based on the peak systolic velocity ratio >2.4. | 24 month | |
Secondary | target lesion revascularisation | Need for target lesion revascularisation after index procedure | 6, 12, and 24 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05712395 -
The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease
|
N/A | |
Active, not recruiting |
NCT04534257 -
Prospective Registry to Investigate the Safety and Efficacy of the Treatment With the Selution Sirolimus Drug Coated Balloon in TASC C and D Atheroma-occlusive Infra-Inguinal Disease in Patients With Chronic Limb Threatening Ischemia From Singapore
|
N/A | |
Recruiting |
NCT04511234 -
Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Completed |
NCT02554266 -
Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon for Treatment of BTK Arteries
|
||
Completed |
NCT03921905 -
Peripheral Artery Disease in Patients With Stable Coronary Artery Disease in General Practice: Prevalence, Management and Clinical Outcomes.
|
||
Not yet recruiting |
NCT06369350 -
Vitamin B6 on Exercise Pressor Reflex on Leg Ischemia-reperfusion
|
Early Phase 1 | |
Recruiting |
NCT04545268 -
Prehabilitation for Cardiac Surgery in Patients With Reduced Exercise Tolerance
|
N/A | |
Recruiting |
NCT02389023 -
Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery
|
N/A | |
Completed |
NCT02522884 -
Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries
|
N/A | |
Completed |
NCT02542267 -
In-Stent Restenosis Post-Approval Study
|
N/A | |
Completed |
NCT02539940 -
Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
|
||
Completed |
NCT02563535 -
Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia
|
Phase 4 | |
Completed |
NCT02228564 -
BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease
|
N/A | |
Completed |
NCT02262949 -
A Prospective Study of the Bard® LifeStent® Solo Vascular Stent System
|
N/A | |
Completed |
NCT02145065 -
First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)
|
N/A | |
Completed |
NCT01743872 -
Optical Imaging Measurement of Intravascular Solution Efficacy Trial
|
N/A | |
Recruiting |
NCT01424020 -
Walking Estimated Limitation Calculated by History - Study 2
|
Phase 4 | |
Active, not recruiting |
NCT01597453 -
NOR-SYS: The Norwegian Stroke in the Young Study
|
N/A |